Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15

Xin Wang, Pádraig D'Arcy, Thomas Caulfield, Aneel Paulus, Kasyapa Chitta, Chitralekha Mohanty, Joachim Gullbo, Asher A Chanan Khan, Stig Linder

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The ubiquitin-proteasome system (UPS) is increasingly recognized as a therapeutic target for the development of anticancer therapies. The success of the 20S proteasome core particle (20S CP) inhibitor bortezomib in the clinical management of multiple myeloma has raised the possibility of identifying other UPS components for therapeutic intervention. We previously identified the small molecule b-AP15 as an inhibitor of 19S proteasome deubiquitinase (DUB) activity. Building upon our previous data, we performed a structure-activity relationship (SAR) study on b-AP15 and identified VLX1570 as an analog with promising properties, including enhanced potency and improved solubility in aqueous solution. In silico modeling was consistent with interaction of VLX1570 with key cysteine residues located at the active sites of the proteasome DUBs USP14 and UCHL5. VLX1570 was found to inhibit proteasome deubiquitinase activity in vitro in a manner consistent with competitive inhibition. Furthermore, using active-site-directed probes, VLX1570 also inhibited proteasome DUB activity in exposed cells. Importantly, VLX1570 did not show inhibitory activity on a panel of recombinant non-proteasome DUBs, on recombinant kinases, or on caspase-3 activity, suggesting that VLX1570 is not an overtly reactive general enzyme inhibitor. Taken together, our data shows the chemical and biological properties of VLX1570 as an optimized proteasome DUB inhibitor. The compound b-AP15 was previously shown to inhibit proteasome DUB (deubiquitinase) activity, leading to proteasome blocking and tumor cell apoptosis. The authors have examined the biological activities of a number of structurally related compounds and describe the analogue VLX1570. This compound is an inhibitor of proteasome DUBs USP14 and UCHL5, whereas other DUBs are not significantly inhibited.

Original languageEnglish (US)
Pages (from-to)1036-1048
Number of pages13
JournalChemical Biology and Drug Design
Volume86
Issue number5
DOIs
StatePublished - Nov 1 2015

Fingerprint

Proteasome Inhibitors
Proteasome Endopeptidase Complex
Derivatives
Ubiquitin
Catalytic Domain
Deubiquitinating Enzymes
Enzyme Inhibitors
Structure-Activity Relationship
Multiple Myeloma
Caspase 3
Computer Simulation
Solubility
Cysteine
Bioactivity
Phosphotransferases
Therapeutics
Apoptosis
Tumors
Cells

Keywords

  • chalcone
  • deubiquitinase
  • in silico modeling
  • inhibitor
  • lead optimization
  • proteasome

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15. / Wang, Xin; D'Arcy, Pádraig; Caulfield, Thomas; Paulus, Aneel; Chitta, Kasyapa; Mohanty, Chitralekha; Gullbo, Joachim; Chanan Khan, Asher A; Linder, Stig.

In: Chemical Biology and Drug Design, Vol. 86, No. 5, 01.11.2015, p. 1036-1048.

Research output: Contribution to journalArticle

Wang, Xin ; D'Arcy, Pádraig ; Caulfield, Thomas ; Paulus, Aneel ; Chitta, Kasyapa ; Mohanty, Chitralekha ; Gullbo, Joachim ; Chanan Khan, Asher A ; Linder, Stig. / Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15. In: Chemical Biology and Drug Design. 2015 ; Vol. 86, No. 5. pp. 1036-1048.
@article{f312c4a389a8404ca0e5bbac4d3560af,
title = "Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15",
abstract = "The ubiquitin-proteasome system (UPS) is increasingly recognized as a therapeutic target for the development of anticancer therapies. The success of the 20S proteasome core particle (20S CP) inhibitor bortezomib in the clinical management of multiple myeloma has raised the possibility of identifying other UPS components for therapeutic intervention. We previously identified the small molecule b-AP15 as an inhibitor of 19S proteasome deubiquitinase (DUB) activity. Building upon our previous data, we performed a structure-activity relationship (SAR) study on b-AP15 and identified VLX1570 as an analog with promising properties, including enhanced potency and improved solubility in aqueous solution. In silico modeling was consistent with interaction of VLX1570 with key cysteine residues located at the active sites of the proteasome DUBs USP14 and UCHL5. VLX1570 was found to inhibit proteasome deubiquitinase activity in vitro in a manner consistent with competitive inhibition. Furthermore, using active-site-directed probes, VLX1570 also inhibited proteasome DUB activity in exposed cells. Importantly, VLX1570 did not show inhibitory activity on a panel of recombinant non-proteasome DUBs, on recombinant kinases, or on caspase-3 activity, suggesting that VLX1570 is not an overtly reactive general enzyme inhibitor. Taken together, our data shows the chemical and biological properties of VLX1570 as an optimized proteasome DUB inhibitor. The compound b-AP15 was previously shown to inhibit proteasome DUB (deubiquitinase) activity, leading to proteasome blocking and tumor cell apoptosis. The authors have examined the biological activities of a number of structurally related compounds and describe the analogue VLX1570. This compound is an inhibitor of proteasome DUBs USP14 and UCHL5, whereas other DUBs are not significantly inhibited.",
keywords = "chalcone, deubiquitinase, in silico modeling, inhibitor, lead optimization, proteasome",
author = "Xin Wang and P{\'a}draig D'Arcy and Thomas Caulfield and Aneel Paulus and Kasyapa Chitta and Chitralekha Mohanty and Joachim Gullbo and {Chanan Khan}, {Asher A} and Stig Linder",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/cbdd.12571",
language = "English (US)",
volume = "86",
pages = "1036--1048",
journal = "Chemical Biology and Drug Design",
issn = "1747-0277",
publisher = "Blackwell",
number = "5",

}

TY - JOUR

T1 - Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15

AU - Wang, Xin

AU - D'Arcy, Pádraig

AU - Caulfield, Thomas

AU - Paulus, Aneel

AU - Chitta, Kasyapa

AU - Mohanty, Chitralekha

AU - Gullbo, Joachim

AU - Chanan Khan, Asher A

AU - Linder, Stig

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The ubiquitin-proteasome system (UPS) is increasingly recognized as a therapeutic target for the development of anticancer therapies. The success of the 20S proteasome core particle (20S CP) inhibitor bortezomib in the clinical management of multiple myeloma has raised the possibility of identifying other UPS components for therapeutic intervention. We previously identified the small molecule b-AP15 as an inhibitor of 19S proteasome deubiquitinase (DUB) activity. Building upon our previous data, we performed a structure-activity relationship (SAR) study on b-AP15 and identified VLX1570 as an analog with promising properties, including enhanced potency and improved solubility in aqueous solution. In silico modeling was consistent with interaction of VLX1570 with key cysteine residues located at the active sites of the proteasome DUBs USP14 and UCHL5. VLX1570 was found to inhibit proteasome deubiquitinase activity in vitro in a manner consistent with competitive inhibition. Furthermore, using active-site-directed probes, VLX1570 also inhibited proteasome DUB activity in exposed cells. Importantly, VLX1570 did not show inhibitory activity on a panel of recombinant non-proteasome DUBs, on recombinant kinases, or on caspase-3 activity, suggesting that VLX1570 is not an overtly reactive general enzyme inhibitor. Taken together, our data shows the chemical and biological properties of VLX1570 as an optimized proteasome DUB inhibitor. The compound b-AP15 was previously shown to inhibit proteasome DUB (deubiquitinase) activity, leading to proteasome blocking and tumor cell apoptosis. The authors have examined the biological activities of a number of structurally related compounds and describe the analogue VLX1570. This compound is an inhibitor of proteasome DUBs USP14 and UCHL5, whereas other DUBs are not significantly inhibited.

AB - The ubiquitin-proteasome system (UPS) is increasingly recognized as a therapeutic target for the development of anticancer therapies. The success of the 20S proteasome core particle (20S CP) inhibitor bortezomib in the clinical management of multiple myeloma has raised the possibility of identifying other UPS components for therapeutic intervention. We previously identified the small molecule b-AP15 as an inhibitor of 19S proteasome deubiquitinase (DUB) activity. Building upon our previous data, we performed a structure-activity relationship (SAR) study on b-AP15 and identified VLX1570 as an analog with promising properties, including enhanced potency and improved solubility in aqueous solution. In silico modeling was consistent with interaction of VLX1570 with key cysteine residues located at the active sites of the proteasome DUBs USP14 and UCHL5. VLX1570 was found to inhibit proteasome deubiquitinase activity in vitro in a manner consistent with competitive inhibition. Furthermore, using active-site-directed probes, VLX1570 also inhibited proteasome DUB activity in exposed cells. Importantly, VLX1570 did not show inhibitory activity on a panel of recombinant non-proteasome DUBs, on recombinant kinases, or on caspase-3 activity, suggesting that VLX1570 is not an overtly reactive general enzyme inhibitor. Taken together, our data shows the chemical and biological properties of VLX1570 as an optimized proteasome DUB inhibitor. The compound b-AP15 was previously shown to inhibit proteasome DUB (deubiquitinase) activity, leading to proteasome blocking and tumor cell apoptosis. The authors have examined the biological activities of a number of structurally related compounds and describe the analogue VLX1570. This compound is an inhibitor of proteasome DUBs USP14 and UCHL5, whereas other DUBs are not significantly inhibited.

KW - chalcone

KW - deubiquitinase

KW - in silico modeling

KW - inhibitor

KW - lead optimization

KW - proteasome

UR - http://www.scopus.com/inward/record.url?scp=84944164063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944164063&partnerID=8YFLogxK

U2 - 10.1111/cbdd.12571

DO - 10.1111/cbdd.12571

M3 - Article

C2 - 25854145

AN - SCOPUS:84944164063

VL - 86

SP - 1036

EP - 1048

JO - Chemical Biology and Drug Design

JF - Chemical Biology and Drug Design

SN - 1747-0277

IS - 5

ER -